

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group has obtained the approval for drug production and registration for Sodium Cromoglicate Eye Drops 2% (0.3ml:6mg) from the National Medical Products Administration of China, being under type 3 chemical drug and regarded as passing the consistency evaluation.

Sodium Cromoglicate Eye Drops is an over-the-counter (OTC) drug mainly used for preventing spring allergic conjunctivitis. The Group is the first of the PRC entities approved for Sodium Cromoglicate single-dose preparation under the new type 3 chemical drug (regarded as passing the consistency evaluation). This product is in single-dose packaging and preservative-free, and can effectively reduce irritation and damage to ocular surface caused by long-term contact with preservatives, resulting in higher safety and meeting the clinical needs for children, people with sensitive ocular surfaces, and others requiring long-term medication.

Following the approval of this product, the Group’s ophthalmic preparations product portfolio has been further improved. It forms a complete ophthalmic drug layout including five major treatment areas: anti-infection, anti-allergy, intraocular pressure lowering, artificial tears and ocular anti-inflammatory, and covers clinical scenarios of many common ophthalmic diseases such as ocular surface infection, allergic eye disease, glaucoma, dry eye syndrome and postoperative ocular surface inflammation.

The Group has implemented a dual-channel layout together for in-hospital prescription drugs and retail OTC by getting through diverse sales scenarios such as hospitals and pharmacies, and continuously expanding its market influence in the track of ophthalmic generic drug. In the field of anti-allergic ophthalmology, the Group has successively obtained approvals for Emedastine Difumarate Eye Drops, Ketotifen Fumarate Eye Drops and this newly approved Sodium Cromoglicate Eye Drops, covering different mechanisms such as stabilizing mast cells and selectively antagonizing histamine receptors, which can meet tiered treatment needs of patients with mild, moderate and severe allergic conjunctivitis. The Group will continue to push forward the research & development and industrialization of ophthalmic preparations, enrich its pipeline of single-dose preservative-free ophthalmic products, and continue to grasp the industry trend of ophthalmic drugs upgrade in the PRC.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 15 October 2026

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Meng Guo, Mr. Chow Hing Yeung, Ms. Qu Wanrong and Mr. Wu Hengyao as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.